ARVN
$12.01
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Recent News
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
Arvinas (NASDAQ:ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi. Chief Executive Officer Randy Teel and Chief Scientific Officer Angela Cacace said the company is ent
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference
Executives from Arvinas (NASDAQ:ARVN) outlined the company’s clinical pipeline and near-term milestones during a presentation at Leerink Partners’ Global Healthcare Conference, emphasizing multiple Phase 1 programs expected to generate data over the coming year. Company overview and focus on clinic
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts
Arvinas’ updated fair value price target has shifted from US$12.81 to US$14.56, a move of about US$1.75 per share that puts a fresh spotlight on the name for many investors. That change aligns with a wave of analyst commentary, with higher price targets in the US$18 to US$20 range being linked to pipeline updates, new leadership, and a tighter focus on upcoming ARV 102 and ARV 393 milestones. Read on to see how these developments are shaping the evolving Arvinas story and what to watch...
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference
Executives from Arvinas (NASDAQ:ARVN) outlined recent pipeline progress and upcoming catalysts at TD Cowen’s 46th Annual Healthcare Conference, highlighting a growing set of Phase 1 programs built on what the company described as a “pivotal trial-proven” protein degradation platform. Dr. Randy Teel
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development. During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The […]